Chronic hand dermatitis (CHD) is a common chronic inflammatory skin condition that has a 1-year prevalence in 10% of the general population and a lifetime prevalence in up to 15%. 1 There is a negative impact on the quality of life for patients with this condition, leading to social and psychological distress that ultimately can decrease an individual's productivity. 2, 3 Although CHD can be difficult to treat, alitretinoin (9-cis retinoic acid) provides a therapeutic option with marked efficacy and good tolerance. There have been studies supporting alitretinoin use for CHD in controlled clinical trials [4] [5] [6] [7] and real-world review.
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The present retrospective chart review includes a followup of a previous patient cohort from a 2014 community dermatology practice chart review, which demonstrated that alitretinoin was a safe and well-tolerated treatment in a realworld practice. 10 The participants in the present study were patients with CHD from 1 dermatology clinic who were prescribed at least 1 dose of alitretinoin from November 2010 until August 2013. The treatment course of this patient population is further reported until January 2017. Participants were prescribed a daily oral dose of alitretinoin, and laboratory assessments were conducted approximately every 2 months.
The average participant age was 57.3 ± 12.2 years, and 60.0% were male. The patient cohort included several types of CHD, such as hyperkeratotic, pompholyx, fingertip, psoriasiform dermatitis, chronic actinic dermatitis, asteatotic dermatitis, and palmoplantar dermatitis. Of the 80 patients with CHD prescribed alitretinoin, 25 (31.3%) did not take the treatment. Fifty-three (96.4%) patients started at 30 mg and 2 (3.6%) patients started at the 10-mg once-daily dosage. Two patients from this cohort had started alitretinoin therapy since August 2013; 1 patient started at 30 mg and the other at 10 mg once daily. Of those who did not take alitretinoin, 11 (44%) were lost to follow-up after the prescription visit, 9 (36.0%) did not have insurance coverage, 3 (12%) did not specify their reason, 1 (4%) had concern over the side effects, and 1 (4%) had concern over cost. Of the 55 (68.8%) participants who took alitretinoin, the median time of treatment was 10 months, the average was 12.6 months, and the ongoing maximum was 71 months. In contrast, the average time of treatment was 7.4 months and the ongoing maximum was 33 months in the 2014 published review. 10 Forty-eight (60%) participants who stopped therapy did so within the first year. The most common reasons to discontinue therapy or decrease dose were either the clearance of disease symptoms or the experience of side effects.
Up to January 2017, 44 (55.0%) patients discontinued treatment. Reasons for discontinuation included the following: 10 (22.7%) had side effects, 10 (22.7%) were lost to follow-up, 8 (18.2%) had cleared symptoms, 7 (15.9%) lost their insurance coverage, 4 (9.1%) had poor response to treatment, 3 (6.8%) did not specify their reason, 1 (2.3%) was attempting to conceive, and 1 (2.3%) discontinued due to cost. Sixteen (29.0%) patients who discontinued therapy had to restart therapy because of moderate-to-severe flareups. The number of patients to reduce the dose increased from 8 (15.0%) patients in the 2014 review 10 to 17 (30.9%) in this 2017 review. During therapy, 17 patients switched to a lower dose of alitretinoin: 10 (58.8%) had cleared symptoms, 6 (35.3%) experienced side effects, and 1 (5.9%) switched due to loss of insurance coverage. The most common side effects were headaches, nausea, joint pain/stiffness, hair loss/thinning, and sun sensitivity. Less common side effects included depression, elevated triglycerides or cholesterol, blurred vision, hand numbness, and edema. One (1.8%) patient who started at 10 mg increased the dose to 30 mg after August 2013 to achieve a stronger response. Since the 2014 review, 10 4 (7.3%) patients have stopped alitretinoin due to abnormal laboratory values, including 1 (1.8%) with elevated triglycerides and 3 (5.5%) with elevated transaminases. Despite improvement in laboratory values upon discontinuation, all 4 patients' disease flared. Currently, 13 (23.6%) participants remain on long-term therapy with good control of their disease.
Alitretinoin is a safe and effective treatment option for CHD in the clinic setting. Although some participants experienced side effects, many of these improved with continued use of the drug or by reducing the dosage. Only a minority of participants required ongoing alitretinoin therapy for control of disease, and no increase in safety signals was noted with long-term therapy. Further studies on a larger population and longer duration of therapy would support these observations from a single community practice.
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